Mutation Resistance Could Differentiate Shionogi/ViiV’s Dolutegravir
This article was originally published in The Pink Sheet Daily
Executive Summary
Full data from the Phase III SPRING-2 trial released at the International AIDs Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.